Clinical Scorecard: A Quick Systematic Review of COVID-19 Treatments Authorized by the U.S. Food and Drug Administration
At a Glance
Category
Detail
Condition
COVID-19
Key Mechanisms
Evaluation of thrombotic, bleeding, and infection risks associated with FDA-authorized COVID-19 treatments including COVID-19 Convalescent Plasma (CCP), monoclonal antibodies, and remdesivir
Target Population
Patients receiving FDA-authorized COVID-19 treatments in clinical trials
Care Setting
Inpatient and outpatient clinical trial settings
Key Highlights
No significant thrombotic risk associated with COVID-19 Convalescent Plasma (CCP) based on corrected data analysis.
Methodologic errors identified in data abstraction and analysis of thrombotic, bleeding, and infection events in prior systematic review.
Non-randomized studies with unmatched controls may bias safety outcome interpretations, especially regarding bleeding and infection risks.
Guideline-Based Recommendations
Diagnosis
Careful differentiation and separate reporting of serious adverse events (SAEs) such as thrombosis, bleeding, and infection in clinical trials.
Management
Interpret safety data from randomized controlled trials (RCTs) preferentially over non-randomized studies to guide treatment decisions.
Avoid summing numerators of overlapping SAEs (e.g., deep venous thrombosis and pulmonary embolism) as separate events.
Monitoring & Follow-up
Monitor for thrombotic, bleeding, and infectious complications during COVID-19 treatment, with attention to baseline patient illness severity.
Risks
No evidence of increased thrombotic risk with CCP; prior reports suggesting increased risk were based on data errors.
Non-RCT data may overestimate risks due to confounding by indication and baseline differences.
Patient & Prescribing Data
Patients enrolled in randomized controlled trials and non-randomized studies receiving CCP, monoclonal antibodies, or remdesivir for COVID-19
Corrected data indicate CCP is associated with fewer thrombotic events compared to controls; monoclonal antibodies and remdesivir show no significant difference in thrombotic events versus controls.
Clinical Best Practices
Use randomized controlled trial data as the primary evidence source for safety assessments of COVID-19 treatments.
Avoid combining overlapping adverse event counts to prevent overestimation of risks.
Consider baseline patient characteristics and concomitant treatments when interpreting safety outcomes, especially in non-randomized studies.
Ensure accurate data abstraction from clinical trial registries and publications to inform systematic reviews.
